Premium
p53 protein overexpression and K‐rascodon 12 mutation in pancreatic ductal carcinoma: Correlation with histologic factors
Author(s) -
Kasuya Kazuhiko,
Watanabe Hidenobu,
Nakasako Toshiaki,
Ajioka Yoichi,
Koyanagi Yasuhisa
Publication year - 1997
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.1997.tb04536.x
Subject(s) - perineural invasion , p53 protein , pathology , lymph node , carcinoma , cancer , pancreatic carcinoma , immunohistochemistry , medicine , pancreatic cancer
The correlation of p53 protein overexpression and the K‐ras codon 12 mutatlon wlth histologlc type, grade of cytologic atypla, depth of lnvasion and other histologlc prognostic factors was studied In paraffin sectlons from 43 ductectatic‐and 70 solid‐type pancreatic ductal carcinomas. Overexpression of p53 was found in 23.3% (10143) of ductectatic carcinomas (17.2% of intraductal and 35.7% of lnvaslve carclnomas) and in 61.4% (43/70) of solid carcinomas. In ductectatic cancers, p53 overexpression was detected In 14.8% (4/27) of carcinomas wlth lowgrade atypla (CAL), 50.0% (5110) of carcinomas wlth high‐grade atypla (CAH) and in 16.7% (In) of mixed low‐ and hlgh‐grade cancers. In the last group, expression was restricted to an area of CAH. In solld cancers, p53 overexpression did not dlffer by histologic type or grade. Overexpresslon of p53 and K‐ras mutatlons did not correlate with histologlc prognostic factors (lymphatic, venous and perineural Invasion, and lymph node metastasls) in ductectatlc and solld cancers or depth of invasion of solld carclnomas. Our data suggest that p53 alteratlon occurs at an early intraductal stage of solld carcinoma, irrespectlve of cellular atypla, but Is low in ductectatic CAL and becomes hlgher In ductectatlc CAH. K‐ras mutatlon, present In a high percentage of tumors of all groups and not correlating with the factors above, showed no changes In frequency with tumor progression.